ClinicalTrials.gg
CompletedNCT02064439EinsteinChoiceUpdated Dec 19, 2017Results posted

Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)

A Phase 3 interventional study of BAY 59-7939 and BAY 59-7939 in Pulmonary Embolism, Thromboembolism and Thrombosis, sponsored by Bayer. Completed at 267 sites in 31 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-12-19.

Sponsored by Bayer · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
3,365
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing rivaroxaban in Pulmonary Embolism — 4 open to participants now, 6 under way, 2 of them phase 3. Rivaroxaban · Pulmonary Embolism.

Enrollment
5th of 20
3,365 · median 241
Started
2014
the only one that year
Phase 3
7 of 20
2 open now
Registered
6th of 20
by date
Lead sponsor
6 of 20
Bayer

Among the 20 studies testing rivaroxaban in Pulmonary Embolism, this one is the 5th largest by enrollment, is the only one that started in 2014, is one of 7 in phase 3, and was the 6th registered.

Pulmonary Embolism

832 studies on the registry are indexed under Pulmonary Embolism; 171 are open to participants now.

Browse Pulmonary Embolism studies →

Open to participants now

4 of the 20 studies testing rivaroxaban in Pulmonary Embolism are open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About rivaroxaban

Rivaroxaban: first FDA approval 2011 (XARELTO), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 129 Pulmonary Embolism studies recruiting now, 109 (84%) set no upper age limit and 5 (4%) stop at 75 or younger; 9 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing rivaroxaban in Pulmonary Embolism, or all of them as a file.
02

Study summary

This is a multicenter, randomized, double-blind, event-driven, superiority study for efficacy.

Patients with confirmed symptomatic DVT (Deep Vein Thrombosis) or PE (Pulmonary embolism) who completed 6 or 12 months of treatment of anticoagulation are eligible for this trial

03

Conditions studied

  • Pulmonary Embolism
  • Thromboembolism
  • Thrombosis
  • Venous Thrombosis
  • Venous Thromboembolism

Keywords

  • deep vein thrombosis
  • pulmonary embolism
  • long-term prevention of recurrent symptomatic VTE
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with confirmed symptomatic PE and/or DVT who have been treated for 6 to 12 months and did not interrupt anticoagulation for longer than 1 week

Exclusion criteria

Exclusion Criteria:

  • Legal lower age limitations (country specific) Indication for therapeutic-dosed anticoagulants Indication for antiplatelet therapy or a conventional non- anti-inflammatory drug (NSAID) Hepatic disease which is associated with coagulopathy leading to a bleeding risk Calculated \< 30 mL/min
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
3,365 participants (actual)

Study arms

  • Experimental
    Arm 1

    Rivaroxaban 10 mg once daily for 12 months

    Drug: BAY 59-7939

  • Experimental
    Arm 2

    Rivaroxaban 20 mg once daily for 12 months

    Drug: BAY 59-7939

  • Active comparator
    Arm 3

    ASA (Acetylsalicylic Acid) 100 mg once daily for 12 months

    Drug: ASA

Interventions

  • 10 mg tablet once daily for 12 months

  • 20 mg tablet once daily for 12 months

  • DrugASA

    100 mg tablet once daily for 12 months

06

What researchers measure

Primary outcomes

  1. Number of Participants With the Composite of Fatal or Non-fatal Symptomatic Recurrent Venous Thromboembolism

    The primary efficacy outcomes (i.e., recurrent venous thromboembolism \[VTE\] defined as composite of fatal or non-fatal symptomatic recurrent VTE, including unexplained death for which pulmonary embolism \[PE\] could not be ruled out) as confirmed by the central independent adjudication committee (CIAC) were considered up to the end of the individual intended duration of treatment. Incidence of the composite of the primary and secondary efficacy outcome and its components are based on the first occurrence to participant.

    Time frame: Up to 12 months, at least 6 months

  2. Number of Participants With First Treatment-emergent Major Bleeding

    The principal safety outcome was major bleeding which was defined according to the criteria of the International Society on Thrombosis and Hemostasis (ISTH) as clinically overt bleeding and associated with a fall in hemoglobin of 2 gram per deciliter (g/dL) or more, or leading to a transfusion of 2 or more units of packed red blood cells or whole blood, or occurring in a critical site, e.g. intracranial, intraspinal, intraocular, pericardial, intra articular, intramuscular with compartment syndrome, retroperitoneal, or contributing to death. Incidence of the composite of the primary and secondary efficacy outcome and its components are based on the first occurrence to participant.

    Time frame: Up to 12 months, at least 6 months

Secondary outcomes

  1. Number of Participants With the Composite of the Primary Efficacy Outcome, Myocardial Infarction, Ischemic Stroke or Systemic Non-CNS Embolism

    The secondary efficacy outcome is the composite of the primary efficacy outcome, myocardial infarction (MI), ischemic stroke or non-central nervous system (CNS) systemic embolism. Incidence of the composite of the primary and secondary efficacy outcome and its components are based on the first occurrence to participant.

    Time frame: Up to 12 months, at least 6 months

  2. Number of Participants With Non-major Bleeding Associated With Study Drug Interruption for > 14 Days

    The secondary safety outcome was clinically relevant non-major (CRNM) bleeding, which was adjudicated by the CIAC using the ASA criteria: the bleeding was non-major and the bleeding was associated with a study medication interruption of more than 14 days.

    Time frame: Up to 12 months, at least 6 months

07

Results

Posted Dec 19, 2017

Participant flow

In total 3439 participants were screened at 244 sites in 31 countries from 05-Mar-2014 (First Patient First Visit) to 15-Mar-2016 (Last Patient First Visit).

Participant flow — Overall Study
MilestoneRivaroxaban (Xarelto, BAY59-7939) 10 mg, ODRivaroxaban (Xarelto, BAY59-7939) 20 mg, ODAcetylsalicylic (ASA) 100 mg, OD
Started112711071131
Completed984969949
Not completed143138182
Withdrew: Adverse event514746
Withdrew: Death023
Withdrew: Withdrawal by subject291826
Withdrew: Protocol violation353
Withdrew: Lost to follow-up134
Withdrew: Non-compliance with study medication211923
Withdrew: Physician decision011
Withdrew: Logistical difficulties652
Withdrew: Efficacy outcome reached181657
Withdrew: Safety outcome reached122010
Withdrew: Other227

Outcome measures

PrimaryNumber of Participants With the Composite of Fatal or Non-fatal Symptomatic Recurrent Venous Thromboembolism

The primary efficacy outcomes (i.e., recurrent venous thromboembolism \[VTE\] defined as composite of fatal or non-fatal symptomatic recurrent VTE, including unexplained death for which pulmonary embolism \[PE\] could not be ruled out) as confirmed by the central independent adjudication committee (CIAC) were considered up to the end of the individual intended duration of treatment. Incidence of the composite of the primary and secondary efficacy outcome and its components are based on the first occurrence to participant.

Time frame:
Up to 12 months, at least 6 months
Reported as:
Number · participants
Number of Participants With the Composite of Fatal or Non-fatal Symptomatic Recurrent Venous Thromboembolism
participantsRivaroxaban (Xarelto, BAY59-7939) 10 mg, ODRivaroxaban (Xarelto, BAY59-7939) 20 mg, ODAcetylsalicylic (ASA) 100 mg, OD
Composite131750
Symptomatic recurrent Deep vein thrombosis (DVT)8929
Symptomatic recurrent PE5619
Death (PE)001
Death (unexplained and PE cannot be ruled out)021
Statistical analysis
  • Rivaroxaban (Xarelto, BAY59-7939) 20 mg, OD vs Acetylsalicylic (ASA) 100 mg, OD · Wald test · p = 0.0001 (P-value and hazard ratio estimates based on stratified proportional hazards model, with stratification based index event (DVT or PE with or without DVT).) · Hazard ratio (hr): 0.34 · 95% CI 0.20 to 0.59
  • Rivaroxaban (Xarelto, BAY59-7939) 10 mg, OD vs Acetylsalicylic (ASA) 100 mg, OD · Wald test · p = <0.0001 (P-value and hazard ratio estimates based on stratified proportional hazards model, with stratification based index event (DVT or PE with or without DVT).) · Hazard ratio (hr): 0.26 · 98% CI 0.14 to 0.47
  • Rivaroxaban (Xarelto, BAY59-7939) 10 mg, OD vs Rivaroxaban (Xarelto, BAY59-7939) 20 mg, OD · Wald test · p = 0.4328 (P-value and hazard ratio estimates based on stratified proportional hazards model, with stratification based index event (DVT or PE with or without DVT).) · Hazard ratio (hr): 1.34 · 95% CI 0.65 to 2.75
PrimaryNumber of Participants With First Treatment-emergent Major Bleeding

The principal safety outcome was major bleeding which was defined according to the criteria of the International Society on Thrombosis and Hemostasis (ISTH) as clinically overt bleeding and associated with a fall in hemoglobin of 2 gram per deciliter (g/dL) or more, or leading to a transfusion of 2 or more units of packed red blood cells or whole blood, or occurring in a critical site, e.g. intracranial, intraspinal, intraocular, pericardial, intra articular, intramuscular with compartment syndrome, retroperitoneal, or contributing to death. Incidence of the composite of the primary and secondary efficacy outcome and its components are based on the first occurrence to participant.

Time frame:
Up to 12 months, at least 6 months
Reported as:
Number · participants
Number of Participants With First Treatment-emergent Major Bleeding
participantsRivaroxaban (Xarelto, BAY59-7939) 10 mg, ODRivaroxaban (Xarelto, BAY59-7939) 20 mg, ODAcetylsalicylic (ASA) 100 mg, OD
Any major bleeding563
Fatal bleeding011
Non-fatal critical organ bleed241
Non-fatal non-critical organ bleeding311
Statistical analysis
  • Rivaroxaban (Xarelto, BAY59-7939) 20 mg, OD vs Acetylsalicylic (ASA) 100 mg, OD · Wald test · p = 0.3235 (P-value and hazard ratio estimates based on stratified proportional hazards model, with stratification based index event (DVT or PE with or without DVT).) · Hazard ratio (hr): 2.01 · 95% CI 0.50 to 8.04
  • Rivaroxaban (Xarelto, BAY59-7939) 10 mg, OD vs Acetylsalicylic (ASA) 100 mg, OD · Wald test · p = 0.5005 (P-value and hazard ratio estimates based on stratified proportional hazards model, with stratification based index event (DVT or PE with or without DVT).) · Hazard ratio (hr): 1.64 · 95% CI 0.39 to 6.84
  • Rivaroxaban (Xarelto, BAY59-7939) 10 mg, OD vs Rivaroxaban (Xarelto, BAY59-7939) 20 mg, OD · Wald test · p = 0.7337 (P-value and hazard ratio estimates based on stratified proportional hazards model, with stratification based index event (DVT or PE with or without DVT).) · Hazard ratio (hr): 1.23 · 95% CI 0.37 to 4.03
SecondaryNumber of Participants With the Composite of the Primary Efficacy Outcome, Myocardial Infarction, Ischemic Stroke or Systemic Non-CNS Embolism

The secondary efficacy outcome is the composite of the primary efficacy outcome, myocardial infarction (MI), ischemic stroke or non-central nervous system (CNS) systemic embolism. Incidence of the composite of the primary and secondary efficacy outcome and its components are based on the first occurrence to participant.

Time frame:
Up to 12 months, at least 6 months
Reported as:
Number · participants
Number of Participants With the Composite of the Primary Efficacy Outcome, Myocardial Infarction, Ischemic Stroke or Systemic Non-CNS Embolism
participantsRivaroxaban (Xarelto, BAY59-7939) 10 mg, ODRivaroxaban (Xarelto, BAY59-7939) 20 mg, ODAcetylsalicylic (ASA) 100 mg, OD
Composite181956
Ischemic stroke422
Non-CNS systemic embolism101
Myocardial infarction014
Symptomatic recurrent DVT8929
Symptomatic recurrent PE5618
Death (PE)001
Death (unexplained and PE cannot be ruled out)011
Death (cardiovascular: myocardial infarction)000
Death (cardiovascular: ischemic stroke)000
Statistical analysis
  • Rivaroxaban (Xarelto, BAY59-7939) 20 mg, OD vs Acetylsalicylic (ASA) 100 mg, OD · Wald test · p = <0.0001 (P-value and hazard ratio estimates based on stratified proportional hazards model, with stratification based index event (DVT or PE with or without DVT).) · Hazard ratio (hr): 0.34 · 95% CI 0.20 to 0.57
  • Rivaroxaban (Xarelto, BAY59-7939) 10 mg, OD vs Acetylsalicylic (ASA) 100 mg, OD · Wald test · p = <0.0001 (P-value and hazard ratio estimates based on stratified proportional hazards model, with stratification based index event (DVT or PE with or without DVT).) · Hazard ratio (hr): 0.32 · 95% CI 0.19 to 0.54
  • Rivaroxaban (Xarelto, BAY59-7939) 10 mg, OD vs Rivaroxaban (Xarelto, BAY59-7939) 20 mg, OD · Wald test · p = 0.8172 (P-value and hazard ratio estimates based on stratified proportional hazards model, with stratification based index event (DVT or PE with or without DVT).) · Hazard ratio (hr): 1.08 · 95% CI 0.57 to 2.06
SecondaryNumber of Participants With Non-major Bleeding Associated With Study Drug Interruption for > 14 Days

The secondary safety outcome was clinically relevant non-major (CRNM) bleeding, which was adjudicated by the CIAC using the ASA criteria: the bleeding was non-major and the bleeding was associated with a study medication interruption of more than 14 days.

Time frame:
Up to 12 months, at least 6 months
Reported as:
Number · participants
Number of Participants With Non-major Bleeding Associated With Study Drug Interruption for > 14 Days
participantsRivaroxaban (Xarelto, BAY59-7939) 10 mg, ODRivaroxaban (Xarelto, BAY59-7939) 20 mg, ODAcetylsalicylic (ASA) 100 mg, OD
Number of Participants With Non-major Bleeding Associated With Study Drug Interruption for > 14 Days121712
Statistical analysis
  • Rivaroxaban (Xarelto, BAY59-7939) 20 mg, OD vs Acetylsalicylic (ASA) 100 mg, OD · Wald test · p = 0.3318 (P-value and hazard ratio estimates based on stratified proportional hazards model, with stratification based index event (DVT or PE with or without DVT).) · Hazard ratio (hr): 1.44 · 95% CI 0.69 to 3.02
  • Rivaroxaban (Xarelto, BAY59-7939) 10 mg, OD vs Acetylsalicylic (ASA) 100 mg, OD · Wald test · p = 0.9726 (P-value and hazard ratio estimates based on stratified proportional hazards model, with stratification based index event (DVT or PE with or without DVT).) · Hazard ratio (hr): 0.99 · 95% CI 0.44 to 2.20
  • Rivaroxaban (Xarelto, BAY59-7939) 10 mg, OD vs Rivaroxaban (Xarelto, BAY59-7939) 20 mg, OD · Wald test · p = 0.3137 (P-value and hazard ratio estimates based on stratified proportional hazards model, with stratification based index event (DVT or PE with or without DVT).) · Hazard ratio (hr): 1.46 · 95% CI 0.70 to 3.06

Adverse events

Collected over From after start of study medication but not more than 2 days after stop of study medication.. Non-serious events are listed at a 0.3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rivaroxaban (Xarelto, BAY59-7939) 10 mg, OD—78/1,127 (6.9%)40/1,127 (3.5%)
Rivaroxaban (Xarelto, BAY59-7939) 20 mg, OD—82/1,107 (7.4%)35/1,107 (3.2%)
Acetylsalicylic (ASA) 100 mg, OD—79/1,131 (7%)38/1,131 (3.4%)
Most frequent serious events
Showing 10 of 199
Most frequent serious events
EventRivaroxaban (Xarelto, BAY59-7939) 10 mg, ODRivaroxaban (Xarelto, BAY59-7939) 20 mg, ODAcetylsalicylic (ASA) 100 mg, OD
PneumoniaInfections and infestations2/11275/11073/1131
OsteoarthritisMusculoskeletal and connective tissue disorders3/11270/11075/1131
Urinary tract infectionInfections and infestations2/11274/11070/1131
Atrial fibrillationCardiac disorders1/11273/11071/1131
SepsisInfections and infestations1/11273/11072/1131
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders1/11273/11073/1131
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)3/11271/11071/1131
Suicide attemptPsychiatric disorders3/11270/11070/1131
FallInjury, poisoning and procedural complications1/11270/11073/1131
Femur fractureInjury, poisoning and procedural complications0/11270/11073/1131
Most frequent other events
Showing 10 of 14
Most frequent other events
EventRivaroxaban (Xarelto, BAY59-7939) 10 mg, ODRivaroxaban (Xarelto, BAY59-7939) 20 mg, ODAcetylsalicylic (ASA) 100 mg, OD
PruritusSkin and subcutaneous tissue disorders8/11273/11073/1131
ConstipationGastrointestinal disorders2/11270/11077/1131
Atrial fibrillationCardiac disorders6/11272/11073/1131
Gastrooesophageal reflux diseaseGastrointestinal disorders1/11275/11076/1131
RashSkin and subcutaneous tissue disorders5/11273/11073/1131
Abdominal pain upperGastrointestinal disorders2/11272/11075/1131
DiarrhoeaGastrointestinal disorders4/11274/11071/1131
VomitingGastrointestinal disorders0/11274/11072/1131
Upper respiratory tract infectionInfections and infestations1/11274/11073/1131
DizzinessNervous system disorders4/11274/11073/1131

Baseline characteristics

Age, Continuous
Age, Continuous(years)Rivaroxaban (Xarelto, BAY59-7939) 10 mg, ODRivaroxaban (Xarelto, BAY59-7939) 20 mg, ODAcetylsalicylic (ASA) 100 mg, ODTotal
Mean58.8 ± 14.757.9 ± 14.758.8 ± 14.758.5 ± 14.7
Sex: Female, Male
Sex: Female, Male(Participants)Rivaroxaban (Xarelto, BAY59-7939) 10 mg, ODRivaroxaban (Xarelto, BAY59-7939) 20 mg, ODAcetylsalicylic (ASA) 100 mg, ODTotal
Female5075054881500
Male6206026431865
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Rivaroxaban (Xarelto, BAY59-7939) 10 mg, ODRivaroxaban (Xarelto, BAY59-7939) 20 mg, ODAcetylsalicylic (ASA) 100 mg, ODTotal
Hispanic or Latino31313092
Not Hispanic or Latino8928998892680
Unknown or Not Reported204177212593
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Rivaroxaban (Xarelto, BAY59-7939) 10 mg, ODRivaroxaban (Xarelto, BAY59-7939) 20 mg, ODAcetylsalicylic (ASA) 100 mg, ODTotal
American Indian or Alaska Native2024
Asian161159159479
Native Hawaiian or Other Pacific Islander1124
Black or African American414936126
White7867727862344
More than one race1056
Unknown or Not Reported135126141402
08

Study locations

267 sites
  • Beverly Hills, California 90211, United States
  • La Jolla, California 92037, United States
  • Ventura, California 93003, United States
  • Denver, Colorado 80262, United States
  • Jacksonville, Florida 32207, United States
  • Columbus, Georgia 31904, United States
  • Joliet, Illinois 60435, United States
  • Rockport, Maine 04856, United States
  • Boston, Massachusetts 02114-2696, United States
  • Boston, Massachusetts 02115, United States
  • Boston, Massachusetts 02215, United States
  • Detroit, Michigan 48202, United States
  • Butte, Montana 59701, United States
  • Las Vegas, Nevada 89169, United States
  • Raleigh, North Carolina 27607, United States
  • Columbus, Ohio 43210-1240, United States
  • Toledo, Ohio 43606, United States
  • Philadelphia, Pennsylvania 19104, United States
  • San Antonio, Texas 78229, United States
  • Fredericksburg, Virginia 22401, United States
  • Bellevue, Washington 98004, United States
  • Seattle, Washington 98104, United States
  • Spokane, Washington 99216, United States
  • Tacoma, Washington 98405-2433, United States
  • Garran, Australian Capital Territory 2605, Australia
  • Concord, New South Wales 2139, Australia
  • Kogarah, New South Wales 2217, Australia
  • Lismore, New South Wales 2480, Australia
  • Randwick, New South Wales 2031, Australia
  • St Leonards, New South Wales 2065, Australia
  • Westmead, New South Wales 2145, Australia
  • Brisbane, Queensland 4029, Australia
  • Clayton, Victoria 3168, Australia
  • Box Hill, 3128, Australia
  • Melbourne, 3004, Australia
  • Redcliffe, 4020, Australia
  • Graz, Steiermark 8036, Austria
  • Innsbruck, Tirol 6020, Austria
  • Wien, 1090, Austria
  • Aalst, 9300, Belgium
  • Bruxelles - Brussel, 1070, Belgium
  • Bruxelles - Brussel, 1200, Belgium
  • Hasselt, 3500, Belgium
  • Leuven, 3000, Belgium
  • Belo Horizonte, Minas Gerais 30150-221, Brazil
  • Porto Alegre, Rio Grande Do Sul, Brazil
  • Campinas, Sao Paulo 13083-970, Brazil
  • Santo André, Sao Paulo 09060-650, Brazil
  • Santo André, Sao Paulo 09190-615, Brazil
  • São Paulo, Sao Paulo 01323-001, Brazil
  • São Paulo, Sao Paulo 04039-004, Brazil
  • Rio de Janeiro, Brazil
  • Sao Paulo, 05403-900, Brazil
  • Edmonton, Alberta T6G 2B7, Canada
  • Victoria, British Columbia V8R 4R2, Canada
  • Saint John, New Brunswick E2L 4L2, Canada
  • Halifax, Nova Scotia B3H 3A7, Canada
  • Hamilton, Ontario L8L 2X2, Canada
  • Hamilton, Ontario L8N 4A6, Canada
  • Hamilton, Ontario L8V 1C3, Canada
  • London, Ontario N6A 4G5, Canada
  • Ottawa, Ontario K1H 8L6, Canada
  • Montreal, Quebec H1T 2M4, Canada
  • Montreal, Quebec H3T 1E2, Canada
  • Montreal, Quebec H3T 1M5, Canada
  • St. Jerome, Quebec J7Z 5T3, Canada
  • Fuzhou, Fujian 350025, China
  • Guangzhou, Guangdong 510080, China
  • Guangzhou, Guangdong 510120, China
  • Nanning, Guangxi 530021, China
  • Shijiazhuang, Hebei 050000, China
  • Harbin, Heilongjiang, China
  • Wuhan, Hubei 430032, China
  • Changsha, Hunan 410011, China
  • Changsha, Hunan 410013, China
  • Nantong, Jiangsu 226001, China
  • Suzhou, Jiangsu 215004, China
  • Changchun, Jilin 130000, China
  • Shengyang, Liaoning 110004, China
  • Shenyang, Liaoning 110001, China
  • Yinchuan, Ningxia 750004, China
  • Xi'an, Shaanxi 710032, China
  • Xi'an, Shaanxi 710061, China
  • Jinan, Shandong 250012, China
  • Qingdao, Shandong 266000, China
  • Taiyuan, Shanxi 030001, China
  • Chengdu, Sichuan 610041, China
  • Kunming, Yunnan 650032, China
  • Hangzhou, Zhejiang 310003, China
  • Hangzhou, Zhejiang 310016, China
  • Wenzhou, Zhejiang 325000, China
  • Beijing, 100020, China
  • Beijing, 100029, China
  • Beijing, 100037, China
  • Beijing, 100053, China
  • Beijing, 100730, China
  • Shanghai, 200001, China
  • Shanghai, 200025, China
  • Shanghai, 200032, China
  • Shanghai, 200233, China

Showing the first 100 of 267 sites across 31 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Weitz JI, Bauersachs R, Beyer-Westendorf J, Bounameaux H, Brighton TA, Cohen AT, Davidson BL, Holberg G, Kakkar A, Lensing AW, Prins M, Haskell L, van Bellen B, Verhamme P, Wells PS, Prandoni P; EINSTEIN CHOICE Investigators. Two doses of rivaroxaban versus aspirin for prevention of recurrent venous thromboembolism. Rationale for and design of the EINSTEIN CHOICE study. Thromb Haemost. 2015 Aug 31;114(3):645-50. doi: 10.1160/TH15-02-0131. Epub 2015 May 21. PubMed 25994838 ↗
  • Flumignan CD, Nakano LC, Baptista-Silva JC, Flumignan RL. Antiplatelet agents for the treatment of deep venous thrombosis. Cochrane Database Syst Rev. 2022 Jul 25;7(7):CD012369. doi: 10.1002/14651858.CD012369.pub2. PubMed 35876829 ↗
  • Weitz JI, Lensing AWA, Prins MH, Bauersachs R, Beyer-Westendorf J, Bounameaux H, Brighton TA, Cohen AT, Davidson BL, Decousus H, Freitas MCS, Holberg G, Kakkar AK, Haskell L, van Bellen B, Pap AF, Berkowitz SD, Verhamme P, Wells PS, Prandoni P; EINSTEIN CHOICE Investigators. Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. N Engl J Med. 2017 Mar 30;376(13):1211-1222. doi: 10.1056/NEJMoa1700518. Epub 2017 Mar 18. PubMed 28316279 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2014 to primary completion in Sep 2016, 30 months.

Results were first posted in Dec 2017, 1 year 2 months after primary completion.

Of 31 phase 3 interventional studies under Pulmonary Embolism, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 57. This study's 30 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 14, 2014
First posted
Feb 17, 2014
StartActual
Mar 5, 2014
Primary completionActual
Sep 22, 2016
CompletionActual
Nov 4, 2016
Results first posted
Dec 19, 2017
Last update
Dec 19, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02064439
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Feb 17, 2014
Start date
Mar 5, 2014
Primary completion
Sep 22, 2016
Completion
Nov 4, 2016
Results posted
Dec 19, 2017
Last update
Dec 19, 2017

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rivaroxaban

Start the discussion